ClinicalTrials.gg
CompletedNCT02993471Updated Mar 12, 2019Results posted

A Study of Ixekizumab in Participants With Plaque Psoriasis

A Phase 1 interventional study of Drug Cocktail and Ixekizumab in Psoriasis, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-12.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
19th of 22
28 · median 156
Started
2016
with 2 others
Phase 1
2 of 22
none open now
Registered
12th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 19th largest by enrollment, is one of 3 that started in 2016, is one of 2 in phase 1, and was the 12th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

This study is known as a "drug interaction study." The purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam) that are metabolized by cytochrome P450. Each participant will complete two study periods. Participants will take the mixture of commonly used drugs (plus vitamin K) by mouth on 3 occasions (prior to treatment with ixekizumab and after 1 and 12 weeks of treatment with ixekizumab). The study will last about 17 weeks, including follow-up. Screening must be completed prior to study start.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females with chronic moderate or severe plaque psoriasis for at least 6 months who are candidates for systemic therapy or phototherapy
  • Men and women of must agree to use a reliable method of and men may not donate sperm for the duration of the study. Women must test negative for pregnancy at screening and agree not to become pregnant during the study and until the first normal period following the end of the study
  • Have a (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m²), inclusive, at screening
  • Have greater than or equal to (≥) 10 percent body surface area (BSA) involvement at screening and first admission to the clinical research unit (CRU)
  • Have both a Static Physicians Global Assessment (sPGA) score of ≥3 and Psoriasis Area Severity Index (PASI) score ≥12 at screening and first admission to the CRU

Exclusion criteria

Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque-type
  • Pregnant or nursing (lactating women)
  • History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
  • Have major surgery within 8 weeks prior to first admission to the clinical research unit or during the study
  • Have a history of lymphoproliferative disease, or signs or symptoms of lymphoproliferative disease, or have active or history of malignant disease, or have uncontrolled cerebrocardiovascular or neuropsychiatric disease
  • Require treatment with the cocktail drugs or with inhibitors of cytochrome P450 (CYP) 3A, CYP2C9, CYP2D6, CYP2C19, CYP1A2, or with inducers of or CYP1A2, or with rifampin (inducer of multiple CYPs) or with substrates of CYP3A, CYP2C9, CYP2D6, CYP2C19, or CYP1A2 with narrow therapeutic indices within 14 days prior to the first administration of the drug cocktail through the end of Week 12 assessments
  • Have any known allergy or to any component of the study cocktail or ixekizumab
  • Have participated in any other study with ixekizumab, secukinumab or brodalumab, or have been prescribed ixekizumab or secukinumab
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Drug Cocktail

    Drug cocktail (caffeine, warfarin \[plus vitamin K\], omeprazole, dextromethorphan, and midazolam) administered orally once in Period 1 (day 1).

    Drug: Drug Cocktail

  • Experimental
    Drug Cocktail + Ixekizumab

    Drug cocktail (caffeine, warfarin \[plus vitamin K\], omeprazole, dextromethorphan, and midazolam) administered orally twice in Period 2 (day 8 and day 85). Ixekizumab administered subcutaneously (SC) on multiple occasions in Period 2.

    Drug: Drug Cocktail · Drug: Ixekizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Cytochrome P450 (CYP450) Substrate-Midazolam

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Cytochrome P450 (CYP450) Substrate (Midazolam)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  2. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Midazolam

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC\[0-∞\]) of CYP450 Substrate (Midazolam)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose

  3. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Warfarin

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate (Warfarin)

    Time frame: Predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose

  4. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Warfarin

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC\[0-∞\]) of CYP450 Substrate (Warfarin)

    Time frame: Predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose

  5. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Dextromethorphan

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate (Dextromethorphan)

    Time frame: Predose, 1, 2, 4, 6, 8, 10, 24, 48, and 72 hours postdose

  6. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Dextromethorphan

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC\[0-∞\]) of CYP450 Substrate (Dextromethorphan)

    Time frame: Predose, 1, 2, 4, 6, 8, 10, 24, 48, and 72 hours postdose

  7. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Omeprazole and Its Metabolite 5-Hydroxyomeprazole

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate (Omeprazole and its metabolite 5-Hydroxyomeprazole)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours postdose

  8. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Omeprazole and Its Metabolite 5-Hydroxyomeprazole

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC\[0-∞\]) of CYP450 Substrate (Omeprazole and its metabolite 5-Hydroxyomeprazole)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours postdose

  9. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Caffeine

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate (Caffeine)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours postdose

  10. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to 48 Hours (AUC[0-48h]) of CYP450 Substrate-Caffeine

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to 48 hours (AUC\[0-48h\]) of CYP450 Substrate (Caffeine)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours postdose

07

Results

Posted Mar 12, 2019

Participant flow

Period 1 (Drug Cocktail)
Participant flow — Period 1 (Drug Cocktail)
MilestoneDrug Cocktail /Drug Cocktail + Ixekizumab
Started28
Received at least 1 dose of study drug28
Completed28
Not completed0
Period 2 (Drug Cocktail + Ixekizumab)
Participant flow — Period 2 (Drug Cocktail + Ixekizumab)
MilestoneDrug Cocktail /Drug Cocktail + Ixekizumab
Started28
Received at least 1 dose of study drug27
Completed26
Not completed2
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Cytochrome P450 (CYP450) Substrate-Midazolam

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Cytochrome P450 (CYP450) Substrate (Midazolam)

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Cytochrome P450 (CYP450) Substrate-Midazolam
nanogram per milliliter (ng/mL)1 mg Midazolam160 mg Ixekizumab + 1 mg Midazolam80 mg Ixekizumab Q2W (Once Every Two Weeks) + 1 mg Midazolam
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Cytochrome P450 (CYP450) Substrate-Midazolam4.56 ± 244.92 ± 244.83 ± 26
PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Midazolam

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC\[0-∞\]) of CYP450 Substrate (Midazolam)

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Midazolam
nanogram*hour per milliliter (ng*h/mL)1 mg Midazolam160 mg Ixekizumab + 1 mg Midazolam80 mg Ixekizumab Q2W + 1 mg Midazolam
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Midazolam16.6 ± 2815.9 ± 2715.4 ± 34
PrimaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Warfarin

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate (Warfarin)

Time frame:
Predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Warfarin
ng/mL10 mg Warfarin160 mg Ixekizumab + 10 mg Warfarin80 mg Ixekizumab Q2W + 10 mg Warfarin
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Warfarin510 ± 26525 ± 22510 ± 23
PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Warfarin

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC\[0-∞\]) of CYP450 Substrate (Warfarin)

Time frame:
Predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Warfarin
ng*h/mL10 mg Warfarin160 mg Ixekizumab + 10 mg Warfarin80 mg Ixekizumab Q2W + 10 mg Warfarin
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Warfarin17600 ± 2917700 ± 3116200 ± 29
PrimaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Dextromethorphan

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate (Dextromethorphan)

Time frame:
Predose, 1, 2, 4, 6, 8, 10, 24, 48, and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Dextromethorphan
ng/mL30 mg Dextromethorphan160 mg Ixekizumab + 30 mg Dextromethorphan80 mg Ixekizumab Q2W + 30 mg Dextromethorphan
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Dextromethorphan0.691 ± 2910.878 ± 2020.658 ± 285
PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Dextromethorphan

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC\[0-∞\]) of CYP450 Substrate (Dextromethorphan)

Time frame:
Predose, 1, 2, 4, 6, 8, 10, 24, 48, and 72 hours postdose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Dextromethorphan
ng*h/mL30 mg Dextromethorphan160 mg Ixekizumab + 30 mg Dextromethorphan80 mg Ixekizumab Q2W + 30 mg Dextromethorphan
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Dextromethorphan11.7 ± 25412.6 ± 2258.53 ± 273
PrimaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Omeprazole and Its Metabolite 5-Hydroxyomeprazole

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate (Omeprazole and its metabolite 5-Hydroxyomeprazole)

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours postdose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Omeprazole and Its Metabolite 5-Hydroxyomeprazole
ng/mL20 mg Omeprazole160 mg Ixekizumab + 20 mg Omeprazole80 mg Ixekizumab Q2W + 20 mg Omeprazole
Omeprazole333 ± 83340 ± 74368 ± 62
5-Hydroxyomeprazole148 ± 55143 ± 57137 ± 46
PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Omeprazole and Its Metabolite 5-Hydroxyomeprazole

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC\[0-∞\]) of CYP450 Substrate (Omeprazole and its metabolite 5-Hydroxyomeprazole)

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours postdose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Omeprazole and Its Metabolite 5-Hydroxyomeprazole
ng*h/mL20 mg Omeprazole160 mg Ixekizumab + 20 mg Omeprazole80 mg Ixekizumab Q2W + 20 mg Omeprazole
Omeprazole1060 ± 104829 ± 129913 ± 107
5-Hydroxyomeprazole519 ± 28475 ± 25455 ± 24
PrimaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Caffeine

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate (Caffeine)

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours postdose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Caffeine
ng/mL100 mg Caffeine160 mg Ixekizumab + 100 mg Caffeine80 mg Ixekizumab Q2W + 100 mg Caffeine
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of CYP450 Substrate-Caffeine2230 ± 192220 ± 222240 ± 22
PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to 48 Hours (AUC[0-48h]) of CYP450 Substrate-Caffeine

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to 48 hours (AUC\[0-48h\]) of CYP450 Substrate (Caffeine)

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours postdose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to 48 Hours (AUC[0-48h]) of CYP450 Substrate-Caffeine
ng*h/mL100 mg Caffeine160 mg Ixekizumab + 100 mg Caffeine80 mg Ixekizumab Q2W + 100 mg Caffeine
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to 48 Hours (AUC[0-48h]) of CYP450 Substrate-Caffeine25000 ± 4822400 ± 5722400 ± 36

Adverse events

Collected over Up To 89 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Drug Cocktail0/28 (0%)0/28 (0%)1/28 (3.6%)
Drug Cocktail + Ixekizumab0/27 (0%)0/27 (0%)7/27 (25.9%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventDrug CocktailDrug Cocktail + Ixekizumab
DiarrhoeaGastrointestinal disorders0/281/27
NauseaGastrointestinal disorders0/281/27
Chest discomfortGeneral disorders0/281/27
Peripheral swellingGeneral disorders0/281/27
Cellulitis of male external genital organInfections and infestations0/281/27
PharyngitisInfections and infestations0/281/27
Upper respiratory tract infectionInfections and infestations0/281/27
ArthralgiaMusculoskeletal and connective tissue disorders0/281/27
Back painMusculoskeletal and connective tissue disorders0/281/27
DizzinessNervous system disorders0/281/27

Baseline characteristics

All enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Overall Study
Mean41.8 ± 14.62
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female7
Male21
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino14
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American1
White25
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Study
United States28
08

Study locations

3 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Avail Clinical Research LLC
    DeLand, Florida 32720, United States
  • High Point Clinical Trials Center
    High Point, North Carolina 27265, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Nov 2017, 10 months.

Results were first posted in Mar 2019, 1 year 3 months after primary completion.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 10 months is close to that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2016
First posted
Dec 15, 2016
StartActual
Dec 22, 2016
Primary completionActual
Nov 21, 2017
CompletionActual
Nov 21, 2017
Results first posted
Mar 12, 2019
Last update
Mar 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02993471
Responsible party
Sponsor
First posted
Dec 15, 2016
Start date
Dec 22, 2016
Primary completion
Nov 21, 2017
Completion
Nov 21, 2017
Results posted
Mar 12, 2019
Last update
Mar 12, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion